PDS Biotechnology Corp — Director's Dealing 2019

Mar 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edge Therapeutics, Inc. (EDGE)
CIK: 0001472091
Period of Report: 2019-03-15

Reporting Person: BARER SOL J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-03-15	Common Stock	M	20000	—	Acquired	678075	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-15	Restricted Stock Units	$	M	20000	Disposed		Common Stock (20000)	Direct

Footnotes

F1: Vesting of RSUs granted to the Reporting Person on August 14, 2018.

F2: These shares are held by Meryl Barer, the wife of the Reporting Person. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

F3: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit.

F4: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria.

F5: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest.